Tag: Novo Nordisk

Novo Nordisk's growth narrative has acquired an uncomfortable new dimension. A Reuters-reported study shows prescriptions for GLP-1 weight-loss drugs among ...

The arithmetic is brutal, and investors know it. Cutting the monthly cost of Ozempic and Wegovy from roughly $1,000 and ...

The Danish pharmaceutical giant finds itself in an uncomfortable position these days: advancing on multiple regulatory fronts while its share ...

The Danish pharma giant is placing its biggest strategic bet on a pill — but the market is still weighing ...

Novo Nordisk is getting one piece of good news that is easy to count: Wegovy has now passed five million ...

Novo Nordisk may have delivered a quarter that looked respectable on paper, but the market’s verdict was harsher. In a ...

Novo Nordisk has opened the door to one of the world's fastest-growing diabetes markets with the launch of Awiqli in ...

Novo Nordisk closed the week at €43.32, adding 1.29% on Friday alone, as a wave of analyst upgrades and a ...

Medicare Part D prescriptions for Wegovy surged nearly 600 percent within six months of the FDA’s March 2024 cardiovascular risk ...

Novo Nordisk is extending its oral Wegovy franchise across multiple fronts simultaneously, with a UK launch, a fresh liver fibrosis ...